Richard Cornall, Eliot Charles, Simon Davis. MiroBio
Antibody research graduates from a top Oxford lab into the biotech world — with $34M to fund R&D work
For the past 15 years the University of Oxford’s Simon Davis has been mapping the surface of T cells, exploring and examining the structures of surface proteins while determining what it takes to manage specific immune cell signaling. And now a group of UK investors says its ready to advance that research toward the clinic, inside a new biotech vehicle they’re setting up to take the tech into the commercial sphere.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
